Find what you were looking for? Share your thoughts with a short survey

King’s Health Partners Programme Director to lead new Haematology developments

Kate Barlow has been appointed to the new role of Director of Strategic Platform Transition and Commercial Development at King’s College London. Kate will begin her new role on 1 May 2020.

In this newly created position, Kate [pictured right] will work within the King’s Kate_BarlowCollege London Research Management and Innovation Directorate, supporting the translation of pioneering research, designing long-term plans for sustainable facilities operations and developing commercial partnerships. An early focus of Kate’s work will be on vector manufacturing capabilities, which is a critical component of the King’s Health Partners Haematology vision and future commercial case. 

This builds on King's Health Partners Haematology’s work in treating adult patients with pioneering CAR T therapy, and our infrastructure that harnesses collaboration between our academic and clinical experts to develop and deliver new therapies.

Speaking about the appointment, Prof Julia Wendon, Executive Medical Director: Clinical Strategy
King's College Hospital and Guy's and St Thomas' NHS Foundation Trusts, said:

This appointment recognises the significant contribution Kate has made to establishing King’s Health Partners Haematology as a strategic priority for our partner organisations, and our future plans to further develop commercial partnerships and manufacturing capabilities.

Prof Ghulam Mufti, Director, King's Health Partners Haematology, added:

The programme is entering an exciting new phase as we work together to provide the best care for patients through innovative and sustainable ways of working, such as our One Team initiatives, and track record of achieving ground-breaking and innovative outcomes.
We wish Kate well, and are excited about our plans to progress, and to have Kate remain as a valued member of the King’s Health Partners Haematology Programme Board.

Following her appointment, Kate said:

I am delighted to have been appointed to this new role. I have thoroughly enjoyed being part of King’s Health Partners Haematology over the last four years and look forward to playing a role in future developments; realising the vision of King’s Health Partners Haematology and the immense opportunities our partnership has in being at the forefront of innovation and research to deliver transformational improvements in patient care.
Thank you to everyone I have worked with in the King’s Health Partners Haematology team and within King’s Health Partners, I look forward to continuing to work with you all in this new and exciting venture.

King’s Health Partners Haematology are currently developing the recruitment process for a new Programme Director to take the programme into its next phase.

King’s Health Partners Haematology is aiming to bring together our strengths in clinical service, research, and education to deliver exceptional outcomes for haematology patients. Our vision is to develop cures and vaccinations for haematological conditions so that future generations do not have to face lives with these diseases.